Discounted Cash Flow (DCF) Analysis Unlevered

ABIONYX Pharma SA (ABNX.PA)

2.06 €

-0.03 (-1.20%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 2.06 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 2.06
Beta 0.292
Diluted Shares Outstanding 20.60
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 0.16%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.271
Total Debt 4.96
Total Equity 42.43
Total Capital 47.39
Debt Weighting 10.46
Equity Weighting 89.54
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate -0.04%-0.02%2.07%0.00%0.00%0.40%0.40%0.40%0.40%0.40%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.21-0.02--0.15-0.17-----
UFCF ----------
WACC
PV UFCF --------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.84
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -2.98
Equity Value -
Shares Outstanding 20.60
Equity Value Per Share -